| Catalog No. | HY107026 |
| Brand | abinScience |
| Species reactivity | Human |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 |
| Purity | >95% purity as determined by SDS-PAGE. |
| Isotype | IgG |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Target | Trk-A, High affinity nerve growth factor receptor, NTRK1, Tropomyosin-related kinase A, Neurotrophic tyrosine kinase receptor type 1, MTC, TRKA, Tyrosine kinase receptor, TRK, p140-TrkA, TRK1-transforming tyrosine kinase protein, gp140trk, Tyrosine kinase receptor A |
| References | 1. Ugolini G, et al. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2985-90. [HY107026] 2. Cattaneo A, et al. Functional blockade of tyrosine kinase A in the rat basal forebrain by a novel antagonistic anti-receptor monoclonal antibody. J Neurosci. 1999 Nov 15;19(22):9687-97. [HY107026] |
| Purification | Protein A/G purified from cell culture supernatant. |
| Biological activity | MNAC13 (200-300 ug/mL, 1 h) specifically binds TrkA and leads to inhibition of NGF-dependent signaling in 3T3 cells overexpressing TrkA [1]. MNAC13 (4 ug/mL, 4 days) effectively blocks NGF induced survival and axonal growth of PC12 cells [2]. MNAC13 (2 or 20 ng/mL) specifically binds to TrkA immune adhesin, but does not bind to TrkB in TrkA-BALB/C 3T3 cells [2]. Western Blot Analysis [1] Cell Line: 3T3 cells overexpressing TrkA Concentration: 200-300 ug/mL Incubation Time: 1 h Result: Significantly inhibited the phosphorylation of TrkA and the phosphorylation level of downstream signaling molecule PLCγ1. MNAC13 (0.9-60 ug; i.p. or s.c.; single dose; 18 h before the formalin test) significantly reduce inflammatory pain in the 5 % formalin solution injected CD1 male mice [1]. MNAC13 (30-70 ug; i.p.; once daily; from day 3 to day 10) significantly reduces neuropathic pain and exhibits long-lasting effects in the chronic constriction injury (CCI) CD1 male mice [1]. MNAC13 (1 ug; i.p.; single dose; 15 min before the test) has a significant synergistic analgesic effect combinated with opioid drugs in the 5 % formalin solution injected CD1 male mice [1]. MNAC13 blocks the effect of TrkA on basal forebrain cholinergic neurons (BFCNs) more significantly and persistently than blocking NGF in MNAC13 hybridoma cells injected Wistar rats [2]. |
| Endotoxin level | < 10 EU/mg |
| Expression system | Mammalian cells |
| Accession | P04629 |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternative name | MNAC13 |
| Clone ID | MNAC13 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |
Anti-Human TrkA Reference Antibody (MNAC13, RUO)
Overview
Images
 SDS-PAGE |
SDS-PAGE for Research Grade Anti-Human NTRK1/TRKA (MNAC13) |
 Bioactivity |
Detects recombinant NTRK1 (Catalog No: HY107012) in indirect ELISA. |